Are acalatinib and acotinib the same? What are the differences between these two medications?

Acalabrutinib and acalabrutinib are actually the same drug. They refer to the same molecule, but there may be some confusion due to different name translations or use of trade names. Acalabrutinib (Acalabrutinib) is the international nonproprietary name (INN) of the drug, while acalabrutinib is its Chinese name on the Chinese market.

1. Ingredients and mechanism of action of drugs

Acotinib (acalatinib) is a selective Bruton's tyrosine kinase (BTK) inhibitor used to treat certain types of hematological malignancies, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). BTK is a key enzyme that participates in the process of B cell receptor signaling and controls the normal function of the immune system. Acotinib effectively inhibits the growth of leukemia or lymphoma cells by selectively inhibiting BTK and blocking B cell signaling.

2. Clinical application of acotinib

Acotinib has been widely used in the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and other hematological tumors. Compared with the first-generation BTK inhibitor ibrutinib (Ibrutinib), acotinib has higher selectivity and more precise inhibitory effect on BTK. This characteristic of acotinib makes its side effects relatively small, especially in cardiovascular aspects. Compared with ibrutinib, acotinib has less cardiotoxicity and brings higher safety to patients.

3. The difference between acalatinib and acalatinib

In fact, acalabrutinib and acalabrutinib are different names for the same drug, so there is no real difference. Acalatinib is its international generic name, while Acalatinib is its Chinese name or trade name in the Chinese market. The molecules, chemical composition, mechanism of action and clinical indications of the drugs are exactly the same. Different names are just the naming habits of the drug in different regions and markets, and do not involve changes in the properties of the drug itself.

4. Approval and marketing of drugs

The approval timing and market conditions for acotinib vary globally. In the United States, acotinib was approved by the FDA in 2017 and has quickly become one of the important drugs for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma. In China, acotinib has also been approved and sold in the domestic market. It has been included in China's medical insurance coverage, providing drug coverage for more patients.

Although acotinib and acalabrutinib have different names, they are actually the same drug and the only difference lies in the translation and use of the names. This drug has a therapeutic effect on certain types of hematological malignancies by selectively inhibiting BTK. Acotinib has high selectivity and minor side effects, and has shown good efficacy in clinical treatment, especially in the treatment of chronic lymphocytic leukemia and mantle cell lymphoma. Patients don't have to worry about any actual differences between the two, as they are the same drug, just with a different name.

Reference materials:https://www.calquence.com/